George Carrum, MD
Hematology · Houston, TXNPI 1851471288
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,136 and has fallen 81.4% since, to $212 in 2025. That places this record below the midpoint for hematology clinicians in TX, where the typical reported total is $822.
Across 80 payments — averaging $22.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$268
- AstraZeneca$250
- Johnson & Johnson$191
- Amgen$151
- Novartis$111
- Astellas Pharma US Inc$65
- plus $741 from 18 others
Across 40 payments — averaging $6361.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$155K
- National Marrow Donor Program$41K
- Astellas Pharma Global Development$33K
- Gilead$25K
- Bristol Myers Squibb$1K
What the payments were for
- Food & beverage$1,75299%
- Education$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 13 | $268 |
| AstraZeneca(2 entities) | 9 | $250 |
| Johnson & Johnson | 7 | $191 |
| Amgen | 7 | $151 |
| Novartis | 5 | $111 |
| Astellas Pharma US Inc | 2 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $65 |
| Dova Pharmaceuticals | 3 | $64 |
| Gilead | 2 | $61 |
| Incyte Corporation | 3 | $56 |
| Merck | 3 | $51 |
| Servier Pharmaceuticals LLC | 2 | $50 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $49 |
| Sanofi | 2 | $46 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Pfizer | 2 | $37 |
| Seagen Inc. | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Rigel Pharmaceuticals, Inc. | 2 | $32 |
| Agios Pharmaceuticals, Inc. | 2 | $29 |
| AMAG Pharmaceuticals, Inc. | 2 | $26 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Coherus Oncology, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CALQUENCE$108
How this compares
$1,778 in reported general payments places this provider in the 50th percentile of 97 hematology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 19 | $281,280 |
| RezurockBelumosudil Mesylate | 14 | $252,488 |
| PrevymisLetermovir | 24 | $189,675 |
| ZarxioFilgrastim-Sndz | 20 | $85,541 |
| Posaconazole | 35 | $50,541 |
| Atovaquone | 25 | $15,747 |
| ValacyclovirValacyclovir Hcl | 96 | $3,524 |
| Ursodiol | 39 | $3,102 |
| Tacrolimus | 19 | $2,497 |
| MicafunginMicafungin Sodium | 12 | $2,202 |
| Famciclovir | 18 | $1,520 |
| Vancomycin Hcl | 21 | $1,378 |
| Acyclovir | 77 | $1,353 |
| Fluconazole | 35 | $1,172 |
| Entecavir | 11 | $1,055 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sanofi-aventis U.S. LLCRezurock | $23 | $252,48814 claims |
| MerckPrevymis | $51 | $189,67524 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $33 | $1,35377 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 97 hematology providers in Texas.
Other hematology in Houston
- Miguel EscobarHouston$767K
- Kelty BakerHouston$229K
- Siddhartha GangulyHouston$119K
- Lawrence RiceHouston$103K
- Modupe IdowuHouston$102K
- Swaminathan IyerHouston$50K
- Jing YeHouston$34K
- Senthil SukumarHouston$31K
- Sa WangHouston$27K
- Uday PopatHouston$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.